Rational biomarker development for the early and minimally invasive monitoring of AML

Sherif Abdelhamed; John T. Butler; Seul Jung; Ding Wen Chen; Gaye Jenkins; Lina Gao; Jeong Y. Lim; Jeffery M. Klco; Terzah M. Horton; Peter Kurre

doi:10.1182/bloodadvances.2021004621

Rational biomarker development for the early and minimally invasive monitoring of AML

Sherif Abdelhamed, John T. Butler, Seul Jung, Ding Wen Chen, Gaye Jenkins, Lina Gao, Jeong Y. Lim, Jeffery M. Klco, Terzah M. Horton, Peter Kurre

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Recurrent disease remains the principal cause for treatment failure in acute myeloid leukemia (AML) across age groups. Reliable biomarkers of AML relapse risk and disease burden have been problematic, as symptoms appear late and current monitoring relies on invasive and cost-ineffective serial bone marrow (BM) surveillance. In this report, we discover a set of unique microRNA (miRNA) that circulates in AML-derived vesicles in the peripheral blood ahead of the general dissemination of leukemic blasts and symptomatic BM failure. Next-generation sequencing of extracellular vesicle-contained small RNA in 12 AML patients and 12 controls allowed us to identify a panel of differentially incorporated miRNA. Proof-of-concept studies using a murine model and patient-derived xenografts demonstrate the feasibility of developing miR-1246, as a potential minimally invasive AML biomarker.

Original language	English (US)
Pages (from-to)	4515-4520
Number of pages	6
Journal	Blood Advances
Volume	5
Issue number	21
DOIs	https://doi.org/10.1182/bloodadvances.2021004621
State	Published - Nov 9 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2021004621

Cite this

@article{8e717bc0fc4e4f679dd066f24e688418,

title = "Rational biomarker development for the early and minimally invasive monitoring of AML",

abstract = "Recurrent disease remains the principal cause for treatment failure in acute myeloid leukemia (AML) across age groups. Reliable biomarkers of AML relapse risk and disease burden have been problematic, as symptoms appear late and current monitoring relies on invasive and cost-ineffective serial bone marrow (BM) surveillance. In this report, we discover a set of unique microRNA (miRNA) that circulates in AML-derived vesicles in the peripheral blood ahead of the general dissemination of leukemic blasts and symptomatic BM failure. Next-generation sequencing of extracellular vesicle-contained small RNA in 12 AML patients and 12 controls allowed us to identify a panel of differentially incorporated miRNA. Proof-of-concept studies using a murine model and patient-derived xenografts demonstrate the feasibility of developing miR-1246, as a potential minimally invasive AML biomarker.",

author = "Sherif Abdelhamed and Butler, {John T.} and Seul Jung and Chen, {Ding Wen} and Gaye Jenkins and Lina Gao and Lim, {Jeong Y.} and Klco, {Jeffery M.} and Horton, {Terzah M.} and Peter Kurre",

note = "Publisher Copyright: {\textcopyright} 2021 by The American Society of Hematology.",

year = "2021",

month = nov,

day = "9",

doi = "10.1182/bloodadvances.2021004621",

language = "English (US)",

volume = "5",

pages = "4515--4520",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "21",

}

TY - JOUR

T1 - Rational biomarker development for the early and minimally invasive monitoring of AML

AU - Abdelhamed, Sherif

AU - Butler, John T.

AU - Jung, Seul

AU - Chen, Ding Wen

AU - Jenkins, Gaye

AU - Gao, Lina

AU - Lim, Jeong Y.

AU - Klco, Jeffery M.

AU - Horton, Terzah M.

AU - Kurre, Peter

PY - 2021/11/9

Y1 - 2021/11/9

N2 - Recurrent disease remains the principal cause for treatment failure in acute myeloid leukemia (AML) across age groups. Reliable biomarkers of AML relapse risk and disease burden have been problematic, as symptoms appear late and current monitoring relies on invasive and cost-ineffective serial bone marrow (BM) surveillance. In this report, we discover a set of unique microRNA (miRNA) that circulates in AML-derived vesicles in the peripheral blood ahead of the general dissemination of leukemic blasts and symptomatic BM failure. Next-generation sequencing of extracellular vesicle-contained small RNA in 12 AML patients and 12 controls allowed us to identify a panel of differentially incorporated miRNA. Proof-of-concept studies using a murine model and patient-derived xenografts demonstrate the feasibility of developing miR-1246, as a potential minimally invasive AML biomarker.

AB - Recurrent disease remains the principal cause for treatment failure in acute myeloid leukemia (AML) across age groups. Reliable biomarkers of AML relapse risk and disease burden have been problematic, as symptoms appear late and current monitoring relies on invasive and cost-ineffective serial bone marrow (BM) surveillance. In this report, we discover a set of unique microRNA (miRNA) that circulates in AML-derived vesicles in the peripheral blood ahead of the general dissemination of leukemic blasts and symptomatic BM failure. Next-generation sequencing of extracellular vesicle-contained small RNA in 12 AML patients and 12 controls allowed us to identify a panel of differentially incorporated miRNA. Proof-of-concept studies using a murine model and patient-derived xenografts demonstrate the feasibility of developing miR-1246, as a potential minimally invasive AML biomarker.

UR - http://www.scopus.com/inward/record.url?scp=85118842552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118842552&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2021004621

DO - 10.1182/bloodadvances.2021004621

M3 - Article

C2 - 34587228

AN - SCOPUS:85118842552

SN - 2473-9529

VL - 5

SP - 4515

EP - 4520

JO - Blood Advances

JF - Blood Advances

IS - 21

ER -

Rational biomarker development for the early and minimally invasive monitoring of AML

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this